Pharmaceutical News

RSS

Tampere University licenses drug for Epidermolysis Bullosa to Theravia

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the Paris region of France.

19 Feb 2025

Generic drugs from India linked to more severe adverse events

Generic drugs manufactured in India are linked to significantly more "severe adverse events" for patients who use them than equivalent drugs produced in the United States, a new study finds.

19 Feb 2025

Regulatory crackdown on online prescriptions of weight-loss drugs

Online pharmacies must now conduct in-person consultations before dispensing weight-loss medications, ensuring safe and appropriate use of high-risk drugs.

19 Feb 2025

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.

19 Feb 2025

FDA-approved osteoporosis drug may treat rare genetic heart disease

A research team co-led by scientists at the University of Arizona College of Medicine – Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease.

18 Feb 2025

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

17 Feb 2025

Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily activities by up to 13 months, though their clinical relevance remains debated.

17 Feb 2025

Icaritin softgel capsules offer new hope for hepatocellular carcinoma patients

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

17 Feb 2025

Diabetes drugs may boost brain health but experts warn of risks

Researchers reviewed 374 studies to explore how GLP-1RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

16 Feb 2025

Prozac's surprising immune-boosting effects could lead to new treatments for sepsis

Antidepressants like Prozac are commonly prescribed to treat mental health disorders, but new research suggests they could also protect against serious infections and life-threatening sepsis.

14 Feb 2025

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumor histology.

14 Feb 2025

Risk of bleeding with blood thinners reduces over time

Blood thinners prescribed after blood clots in leg or lung initially increase the risk of bleeding, especially in women and elderly.

14 Feb 2025

Top California democrats clash over how to rein in drug industry middlemen

California Gov. Gavin Newsom and state legislators in Sacramento seem to agree: Prescription drug prices are too high.

13 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

12 Feb 2025

An Arm and a Leg: How do you deal with wild drug prices?

Prices for brand-name drugs in the U.S. are three times what the same drugs cost in other countries. And in a recent KFF survey, 3 in 10 adults reported not taking their medicine as prescribed at some point in the past year because of costs.

12 Feb 2025

One shot to lower cholesterol for life? Scientists unlock a groundbreaking gene therapy

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction without altering DNA, offering a potential one-time treatment for high cholesterol.

11 Feb 2025

Many Americans take supplements for immune support, but doctor recommendations are low

Study finds 11% of U.S. adults used dietary supplements for immune support pre-pandemic, emphasizing the importance of healthcare professional recommendations.

11 Feb 2025

Targeted polymersomes boost methotrexate efficacy for aggressive choriocarcinoma treatment

Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma,

11 Feb 2025

Advances in the design and synthesis of isosteviol derivatives

Announcing a new publication for Acta Materia Medica journal. Isosteviol and its derivatives, diterpene compounds with a wide range of biological activities, play important antiviral, antibacterial, antioxidant, antitumor, analgesic, anti-inflammatory, antipyretic, antifungal, and anticardiovascular disease roles.

11 Feb 2025

Pharmaceutical News

Tampere University licenses drug for Epidermolysis Bullosa to Theravia

Generic drugs from India linked to more severe adverse events

Regulatory crackdown on online prescriptions of weight-loss drugs

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

FDA-approved osteoporosis drug may treat rare genetic heart disease

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?

Icaritin softgel capsules offer new hope for hepatocellular carcinoma patients

Diabetes drugs may boost brain health but experts warn of risks

Prozac's surprising immune-boosting effects could lead to new treatments for sepsis

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Risk of bleeding with blood thinners reduces over time

Top California democrats clash over how to rein in drug industry middlemen

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

An Arm and a Leg: How do you deal with wild drug prices?

One shot to lower cholesterol for life? Scientists unlock a groundbreaking gene therapy

Many Americans take supplements for immune support, but doctor recommendations are low

Targeted polymersomes boost methotrexate efficacy for aggressive choriocarcinoma treatment

Advances in the design and synthesis of isosteviol derivatives

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Latest News